论文部分内容阅读
对初诊T2DM人分别应用来得时、CSII强化治疗及预混胰岛素治疗2周,然后CSII强化治疗组停药。12周后比较治疗情况。结果显示2周后来得时组血糖、依从性、满意度与CSII组无统计学差异(P>0.05),而优于预混胰岛素组(P<0.05),三组间胰岛素用量无显著性差异(P>0.05)。12周后来得时组血糖、HbA1C明显优于CSII治疗后停用药组及预混胰岛素组(P<0.01),依从性、满意度优于预混胰岛素组(P<0.05),胰岛素用量来得时组小于预混胰岛素组(P<0.01)。结论一日一次注射的甘精胰岛素为糖尿病人提供了一种有效、安全的治疗方案。
The newly diagnosed T2DM patients were used to obtain time, CSII intensive treatment and premixed insulin treatment for 2 weeks, and then CSII intensive treatment group withdrawal. After 12 weeks more treatment. The results showed that there was no significant difference between the two groups (P> 0.05), but better than the premixed insulin group (P <0.05), there was no significant difference in insulin dosage between the three groups (P> 0.05). After 12 weeks, HbA1C was significantly better than that of the drug-free group and the premixed insulin group after CSII treatment (P <0.01), and the compliance was better than that of the premixed insulin group (P <0.05) Group was less than premixed insulin group (P <0.01). Conclusion Glargine injected once a day provides an effective and safe treatment for diabetic patients.